Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $6.3 million.

  • Amphastar Pharmaceuticals' Interest Expenses fell 618.09% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year decrease of 2426.44%. This contributed to the annual value of $30.3 million for FY2024, which is 1172.77% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Interest Expenses is $6.3 million, which was down 618.09% from $6.3 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Interest Expenses high stood at $13.7 million for Q3 2023, and its period low was $86000.0 during Q2 2021.
  • For the 5-year period, Amphastar Pharmaceuticals' Interest Expenses averaged around $4.2 million, with its median value being $3.6 million (2023).
  • In the last 5 years, Amphastar Pharmaceuticals' Interest Expenses soared by 232084.81% in 2023 and then crashed by 5111.66% in 2024.
  • Over the past 5 years, Amphastar Pharmaceuticals' Interest Expenses (Quarter) stood at $168000.0 in 2021, then skyrocketed by 214.29% to $528000.0 in 2022, then surged by 1690.91% to $9.5 million in 2023, then tumbled by 32.05% to $6.4 million in 2024, then fell by 2.19% to $6.3 million in 2025.
  • Its last three reported values are $6.3 million in Q3 2025, $6.3 million for Q2 2025, and $6.3 million during Q1 2025.